Pigment epithelium-derived factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal proteolysis1,2

Neoplasia

Volumn 13, Issue 7, 2011, Pages 633-642

  Ladhani, Omar ^a   Sánchez Martinez, Cristina ^a,b   Orgaz, Jose L ^c,d   Jimenez, Benilde ^c   Volpert, Olga V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Biomedical Research and Technological Development Institute   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; MATRIX METALLOPROTEINASE 14; PIGMENT EPITHELIUM DERIVED FACTOR; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL SHAPE; CELL STRUCTURE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME LOCALIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; MELANOMA CELL; MESENCHYME; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

EID: 79960107886     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11446     Document Type: Article

References (51)

1. Chaffer C and Weinberg R (2011). A perspective on cancer cell metastasis. Science 6024, 1559-1564.
2. Kalluri R and Weinberg RA (2009). The basics of epithelial-mesenchymal transition. J Clin Invest 119, 1420-1428.
3. Hegerfeldt Y, Tusch M, Brocker EB, and Friedl P (2002). Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, ß1-integrin function, and migration strategies. Cancer Res 62, 2125-2130.
4. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Brocker EB, and Friedl P (2003). Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 160, 267-277.
5. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, Sahai E, and Marshall CJ (2008). Rac activation and inactivation control plasticity of tumor cell movement. Cell 135, 510-523.
6. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, Stack MS, and Friedl P (2007). Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 9, 893-904.
7. Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, and Sahai E (2006). ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol 16, 1515-1523.
8. Sahai E and Marshall CJ (2003). Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 5, 711-719.
9. Dove A (2002). MMP inhibitors: glimmers of hope amidst clinical failures. Nat Med 8, 95.
10. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, and Bouck NP (1999). Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285, 245-248.
11. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, and Bouck NP (2002). Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium- derived factor. Nat Med 8, 349-357.
12. Aurora AB, Biyashev D, Mirochnik Y, Zaichuk TA, Sanchez-Martinez C, Renault MA, Losordo D, and Volpert OV (2010). NF-?B balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. Blood 116, 475-484.
13. Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, and Volpert OV (2004). Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 199, 1513-1522.
14. Orgaz JL, Ladhani O, Hoek KS, Fernandez-Barral A, Mihic D, Aguilera O, Seftor EA, Bernad A, Rodriguez-Peralto JL, Hendrix MJ, et al. (2009). Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma. Oncogene 28, 4147-4161.
15. Garcia M, Fernandez-Garcia NI, Rivas V, Carretero M, Escamez MJ, Gonzalez- Martin A, Medrano EE, Volpert O, Jorcano JL, Jimenez B, et al. (2004). Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium- derived factor. Cancer Res 64, 5632-5642.
16. Lu C, Li XY, Hu Y, Rowe RG, and Weiss SJ (2010). MT1-MMP controls human mesenchymal stem cell trafficking and differentiation. Blood 115, 221-229.
17. Sabeh F, Shimizu-Hirota R, and Weiss SJ (2009). Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol 185, 11-19.
18. Mazzone M, Baldassarre M, Beznoussenko G, Giacchetti G, Cao J, Zucker S, Luini A, and Buccione R (2004). Intracellular processing and activation of membrane type 1 matrix metalloprotease depends on its partitioning into lipid domains. J Cell Sci 117, 6275-6287.
19. Yana I and Weiss SJ (2000). Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 11, 2387-2401.
20. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, Schade van Westrum S, Crabbe T, Clements J, d'Ortho MP, and Murphy G (1998). The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 273, 871-880.
21. Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y, and Seiki M (1998). TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 273, 16098-16103.
22. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, and Goldberg GI (1995). Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270, 5331-5338.
23. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, and Mueller SC (2006). Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66, 3034-3043.
24. Seftor EA, Brown KM, Chin L, Kirschmann DA, Wheaton WW, Protopopov A, Feng B, Balagurunathan Y, Trent JM, Nickoloff BJ, et al. (2005). Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Cancer Res 65, 10164-10169.
25. Hendrix MJ, Seftor EA, Chu YW, Seftor RE, Nagle RB, McDaniel KM, Leong SP, Yohem KH, Leibovitz AM, Meyskens FL Jr, et al. (1992). Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J Natl Cancer Inst 84, 165-174.
26. Li G, Satyamoorthy K, and Herlyn M (2001). N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 61, 3819-3825.
27. Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, et al. (2005). Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 65, 5144-5152.
28. Gadea G, Sanz-Moreno V, Self A, Godi A, and Marshall CJ (2008). DOCK10- mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells. Curr Biol 18, 1456-1465.
29. Pinner S and Sahai E (2008). PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 10, 127-137.
30. Burridge K and Wennerberg K (2004). Rho and Rac take center stage. Cell 116, 167-179.
31. Smith A, Bracke M, Leitinger B, Porter JC, and Hogg N (2003). LFA-1- induced T cell migration on ICAM-1 involves regulation of MLCK-mediated attachment and ROCK-dependent detachment. J Cell Sci 116, 3123-3133.
32. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, et al. (1996). Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245-248.
33. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, and Kaibuchi K (1996). Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271, 20246-20249.
34. Chrzanowska-Wodnicka M and Burridge K (1996). Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol 133, 1403-1415.
35. Worthylake RA, Lemoine S, Watson JM, and Burridge K (2001). RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 154, 147-160.
36. Keely PJ, Westwick JK, Whitehead IP, Der CJ, and Parise LV (1997). Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 390, 632-636.
37. Dass CR, Ek ET, and Choong PF (2008). PEDF as an emerging therapeutic candidate for osteosarcoma. Curr Cancer Drug Targets 8, 683-690.
38. Meyer C, Notari L, and Becerra SP (2002). Mapping the type I collagenbinding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J Biol Chem 277, 45400-45407.
39. Bilak MM, Becerra SP, Vincent AM, Moss BH, Aymerich MS, and Kuncl RW (2002). Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons. J Neurosci 22, 9378-9386.
40. Bernard A, Gao-Li J, Franco CA, Bouceba T, Huet A, and Li Z (2009). Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium- derived factor. J Biol Chem 284, 10480-10490.
41. Notari L, Baladron V, Aroca-Aguilar JD, Balko N, Heredia R, Meyer C, Notario PM, Saravanamuthu S, Nueda ML, Sanchez-Sanchez F, et al. (2006). Identification of a lipase-linked cell membrane receptor for pigment epithelium- derived factor. J Biol Chem 281, 38022-38037.
42. Friedl P and Wolf K (2003). Proteolytic and non-proteolytic migration of tumour cells and leucocytes. Biochem Soc Symp, 277-285.
43. Fisher KE, Sacharidou A, Stratman AN, Mayo AM, Fisher SB, Mahan RD, Davis MJ, and Davis GE (2009). MT1-MMP- and Cdc42-dependent signaling co-regulate cell invasion and tunnel formation in 3D collagen matrices. J Cell Sci 122, 4558-4569.
44. Smith ND, Schulze-Hoepfner FT, Veliceasa D, Filleur S, Shareef S, Huang L, Huang XM, and Volpert OV (2008). Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism. J Urol 179, 2427-2434.
45. Fernandez-Garcia NI, Volpert OV, and Jimenez B (2007). Pigment epithelium- derived factor as a multifunctional antitumor factor. J Mol Med 85, 15-22.
46. Mori H, Gjorevski N, Inman JL, Bissell MJ, and Nelson CM (2009). Selforganization of engineered epithelial tubules by differential cellular motility. Proc Natl Acad Sci USA 106, 14890-14895.
47. Gonzalo P, Guadamillas MC, Hernandez-Riquer MV, Pollan A, Grande-Garcia A, Bartolome RA, Vasanji A, Ambrogio C, Chiarle R, Teixido J, et al. (2010). MT1- MMP is required for myeloid cell fusion via regulation of Rac1 signaling. Dev Cell 18, 77-89.
48. Van Goethem E, Poincloux R, Gauffre F, Maridonneau-Parini I, and Le Cabec V (2010). Matrix architecture dictates three-dimensional migration modes of human macrophages: differential involvement of proteases and podosome-like structures. J Immunol 184, 1049-1061.
49. Bornstein P (1995). Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 130, 503-506.
50. Jeon S, Kim NH, Koo BS, Lee HJ, and Lee AY (2007). Bee venom stimulates human melanocyte proliferation, melanogenesis, dendricity and migration. Exp Mol Med 39, 603-613.
51. Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A, Shifrin V, Beckmann R, Polsky C, and Volpert OV (2009). Short pigment epithelial-derived factor- derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res 15, 1655-1663.